U.S. Markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
114.65-0.84 (-0.73%)
At close: 4:00PM EST
Sign in to post a message.
  • R
    Rob
    JMP Securities is not the only financial services company getting on board the CRISPR train in recent days. On Monday, Barclays analyst Gena Wang dramatically increased her price target on the stock to $140 per share from the previous $113, while keeping an overweight (again, buy) recommendation. Wang was particularly impressed by the company's progress in several of its clinical programs, as indicated in its fourth-quarter earnings release published last month.
    Other companies remain optimistic about CRISPR's prospects. In the wake of those earnings, Oppenheimer raised its price target by 13% to $187 per share; almost needless to say, it has the equivalent of a buy recommendation on the stock. Goldman Sachs actually lowered its price target slightly (to $189 from $193) and maintained its neutral rating, but the bank's latest level is now 63% above the current share price.
  • W
    Wasabi
    Just a reminder that everyone is starting to look at CRISPR for their Portfolio- following is the article from Motley Fool:
    CRISPR Therapeutics is at the forefront of treating various types of cancer and hereditary blood disorders via immuno- and gene therapy. Each year, about 360,000 babies worldwide are born with either sickle cell disease (SCD) or beta thalassemia. In the case of the former, the disease distorts the shape of patients' hemoglobin. This, in turn, can cause a life-threatening condition called a vaso-occlusive crisis (VOC), in which irregular-shaped red blood cells clump up and constrict blood vessels. Beta thalassemia can significantly reduce a patients' level of hemoglobin. Patients who suffer from either condition require frequent blood transfusions and hospitalization. There is no cure for the two disorders aside from a bone marrow transplant.
    But CRISPR Therapeutics might be coming to the rescue. In phase 1/2 clinical trials, patients who received its CTX001 gene therapy transfusion saw their hemoglobin levels return to normal, were free of VOCs, and no longer depended on transfusions. Additionally, the company's CTX110 immunotherapy managed to eliminate tumor activity completely in 4 out of 11 patients with lymphoma. The patients all had advanced-stage cancer and went through two to five different therapies before enrolling in CTX110 trials.
    At the moment, pharma companies that make drugs to treat SCD are valued at upwards of $3 billion, while biotechs that successfully advance immunotherapies to market could see up to $21 billion in valuation. Given CRISPR Therapeutics' $9.9 billion market cap, the stock still has quite a bit to go before it might be considered overvalued. The company also has more than $1.69 billion in cash with just $348.9 million per year in losses. Given the strength of its science and its financial health, this is one biotech that's sure to add wealth to your portfolio.
  • C
    Charles
    Looking at the recent drop from another perspective: this stock has dropped almost 100 its from the high, but on March 9th, 2020 it was 37.64 and today it is 114.65...have the long term view...the science is proven and we have great results...I am happy even if it drops more...good news coming...hang tough.
    Bullish
  • V
    VirginiaLova
    CRISPR Therapeutics to Participate in Upcoming Investor Conferences
    ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

    Barclays Global Healthcare Conference
    Date: Tuesday, March 9, 2021
    Time: 10:20 a.m. ET

    33rd Annual Roth Conference
    Date: Monday, March 15, 2021
    Time: 1:30 p.m. ET

    A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.
    Bullish
  • R
    Rob
    It’s funny how everyone is thinking that the company they have invested in has problems and it dropped, on each company board here on Yahoo Finance, when in reality it is a whole market situation because of the bond yields. It has nothing to do with any particular company, be it this one or any other.

    I see CRSP being in the same situation as before, having tremendous potential and waiting for important research and testing results this year. The price action has nothing to do with the company’s fundamentals.
    Bullish
  • r
    robert
    This is a critical test for CRSP. Right now it is resting squarely on the 200 day moving average having well breached the 50 and 100 day averages. We are nearing capitulation right now. Hopefully the 200 day holds. Even it if it doesn't CRSP isn't going down forever. But this for sure is a test. It is extremely oversold on the relative strength index. Common sense should kick in soon and the market should quit taking the genomics names, which have a very solid future, through the wood chipper. Hang on for a little longer longs blue skies are ahead.
    Bullish
  • C
    Charlie
    Looking into the crystal ball I have on my desk, I would think large cap value (and other value) stocks to top out mid to late summer. The growth stocks and sectors will start awakening again. Growth stocks are slightly down YTD - small cap the most - after significant rises last year and early this year. There is nothing that is going to hold back innovative and disruptive growth companies though. The future is bright. Particularly for the best of the best, and CRSP, I believe is one of those.
    Bullish
  • T
    Travis
    Do people that follow CRSP do the math and think CRSP will someday be worth 1 Trillion dollar company? I would like to know your thoughts by the numbers. If this tech is used to cure so many different things....what does the value look like in 10 years? ideas please. thanks in advance. Just doing some reasearch.
    Bullish
  • Z
    ZIM
    Crispr Therapeutics: Paving The Way For The Genomic Revolution, But Perhaps Too Early To Go All-In
    Mar. 01, 2021 9:34 AM ET | by BK Tan

    (from article, SeekingAlpha)

    Summary

    We have come a long way from medicine of the past, and technology will serve to accelerate the adoption of genomics as mainstream medicine.
    CRSP, led by the original founders of the CRISPR/Cas9 gene-editing technology, has significant potential in their pipeline.
    A bottom-up, risk-adjusted DCF for each of its pipeline components reveals that it is roughly at fair value based on the price at the time of writing.
    Because of the probabilistic nature of its pipeline at this stage, I believe it is prudent to continue observing for more positive indications in its clinical trials that can increase the expected value of the treatments, before considering a large stake in the firm.

    Introduction

    The paradigm of healthcare has shifted tremendously over the centuries. Indeed, we have come a long way from the prescription of spiritual cures to where we are now with medical technology and advanced chemical synthesis of pharmaceutical products seeking to target even the vilest of illnesses. But much more lies in store for the future of medicine. Previously thought to be impossible due to the large-scale computing power required, scientists sequenced the first human genome in 2003. And with the discovery of the CRISPR/Cas9 gene editing techniques, a new paradigm of medicine has emerged – the genomic revolution which seeks to revolutionize treatments to target the very fundamental unit of life itself. Pioneering this technology are 2020 Chemistry Nobel Prize winners Jennifer Doudna and Emmanuelle Charpentier who stand at the helm of Crispr Therapeutics (CRSP). Understandably, there is much reason to believe in the expertise of these scientists to guide the future of cures in the genomic therapeutic space.
    Bullish
  • J
    Jaya Prakash Naveen
    I bought 200 shares at $158, I need money and need to sell them. Any idea if there are any catalysts that would push the price higher?
  • V
    VirginiaLova
    Extremely Bullish update on CTX001 from Vertex at minute 3-5 and 16-20 — this is the new paradigm in medicine. https://wsw.com/webcast/cowen81/register.aspx?conf=cowen81&page=vrtx&mobile=True&url=https://wsw.com/webcast/cowen81/vrtx/2009988
    Cowen 41st Annual Health Care Conference
    wsw.com
    Bullish
  • C
    Chuck
    6 weeks ago, $CRSP was at $220. It’s currently trading at $103, down more than 50%. I’ll take $ARWR all day long.
    Bullish
  • A
    Ag
    CRSP 200 DMA is about $110.00 our lowest this am was 112.28 - We could re bound from here. not sure CRSP will break the 200
    Neutral
  • V
    VirginiaLova
    To advance its programs, CRISPR Therapeutics is building a new cell therapy manufacturing facility in Framingham, Massachusetts, as reported in Area Development (https://www.areadevelopment.com/newsItems/6-29-2020/crispr-therapeutics-framingham-massachusetts.shtml). According to Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, “We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We look forward to bringing our facility online rapidly. In addition to building out this internal manufacturing capacity, we will continue to work closely with our key manufacturing partners globally."
    Bullish
  • T
    Terry
    This market sell off is getting better ridiculously overdone now!? My growth stocks will be value stocks soon! Nothing majorly fundamentally changed! It’s tough to take 5-10% hit most days 3 weeks in a rows! Diamond hands.... hey! $CRSP $TDOC $PACB $NIO $TSLA $IPOE $BFT
  • R
    Roy
    looks like the other firms are out for C Woods. very pointed selling (not buying) on ARK owned product, crispr is just one of them. Ok for them but not reddit.
    that's what happens when you post every trade every day. nice idea, but they will know you well enough to manipulate you. also media bragging didnt help.
  • T
    Tom
    People on here are so negative. Remember the reason you invested. This is the future of medicine. Be patient, this stock will be massive in the years to come this is just a speedbump in the very long road ahead.
    Bullish
  • V
    VirginiaLova
    Now scientists are writing CRISPR "programs" to take actions on multiple genes at the same time. They can turn stem cells into neurons that make up the central nervous system, which could have implications for creating healthy cells to replace problem cells in people with Alzheimer's or ALS. Newly developed mRNA technology could be combined with CRISPR to change the way clinicians treat diseases.

    To advance its programs, CRISPR Therapeutics is building a new cell therapy manufacturing facility in Framingham, Massachusetts, as reported in Area Development (https://www.areadevelopment.com/newsItems/6-29-2020/crispr-therapeutics-framingham-massachusetts.shtml). According to Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, “We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We look forward to bringing our facility online rapidly. In addition to building out this internal manufacturing capacity, we will continue to work closely with our key manufacturing partners globally."
    Bullish
  • S
    Simon
    As said earlier, major pain and his bear comrades have taken over the market. There's indiscriminate selling so don't try to make sense of stocks movements. If you're an investor, anchor down to weather the storm. Seasoned investors have been here many times before. GLTA and go CRSP!
    Bullish
  • V
    VirginiaLova
    VERTEX’s CEO called CTX001 (SCD & BT) a cure. She said that beyond her CF platform, the company is most excited about the CTX001 potential. And today, Tony Ho at CRSP gave an interview on CRSP. It is likely that Vertex is ready to buy Crispr as it is developing a cure for their prime platform, Cystic Fibrosis.
    Bullish